NCT04268888 (TACE-3) is a Phase 2, PHASE3 clinical trial of Nivolumab and TACE/TAE in Hepatocellular Carcinoma, sponsored by The Clatterbridge Cancer Centre NHS Foundation Trust.

Who is sponsoring NCT04268888?

NCT04268888 is sponsored by The Clatterbridge Cancer Centre NHS Foundation Trust.

What drugs are being tested in NCT04268888?

Interventions in NCT04268888: Nivolumab and TACE/TAE, TACE/TAE.

What condition does NCT04268888 study?

NCT04268888 studies Hepatocellular Carcinoma.

Is NCT04268888 still recruiting?

NCT04268888 is currently suspended. Last updated 26 February 2025.

Last reviewed 2025-02-26 · How we verify

NCT04268888: TACE-3

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC

Suspended Phase 2, PHASE3 Last updated 26 February 2025

What this trial tests

Phase 2, PHASE3 trial testing Nivolumab and TACE/TAE in Hepatocellular Carcinoma in 522 participants. Suspended.

Timeline

8 May 2019

Primary endpoint
1 August 2025

30 June 2026

Quick facts

Lead sponsor	The Clatterbridge Cancer Centre NHS Foundation Trust
Phase	Phase 2, PHASE3
Status	Suspended
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	522
Start date	8 May 2019
Primary completion	1 August 2025
Estimated completion	30 June 2026
Sites	2 locations across France, United Kingdom

Drugs / interventions tested

Nivolumab and TACE/TAE — full drug profile →
TACE/TAE

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

The Clatterbridge Cancer Centre NHS Foundation Trust

Who can join

16 and older, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the addition of nivolumab to TACE/TAE in the treatment of patients with intermediate stage hepatocellular carcinoma. All patients will receive TACE/TAE and half will receive nivolumab.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Advances in immunotherapy for hepatocellular carcinoma.
Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. · · 2021 · cited 1002× · PMID 33850328 · DOI 10.1038/s41575-021-00438-0
Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
Oura K, Morishita A, Tani J, Masaki T. · · 2021 · cited 340× · PMID 34071550 · DOI 10.3390/ijms22115801
Emerging Therapies for Hepatocellular Carcinoma (HCC).
Chakraborty E, Sarkar D. · · 2022 · cited 236× · PMID 35681776 · DOI 10.3390/cancers14112798
Emerging immunotherapy for HCC: A guide for hepatologists.
Foerster F, Gairing SJ, Ilyas SI, Galle PR. · · 2022 · cited 185× · PMID 35253934 · DOI 10.1002/hep.32447
Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies.
Giraud J, Chalopin D, Blanc JF, Saleh M. · · 2021 · cited 172× · PMID 33815418 · DOI 10.3389/fimmu.2021.655697
Hepatocellular carcinoma: signaling pathways and therapeutic advances.
Zheng J, Wang S, Xia L, Sun Z, et al · · 2025 · cited 142× · PMID 39915447 · DOI 10.1038/s41392-024-02075-w
Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma.
Tümen D, Heumann P, Gülow K, Demirci CN, et al · · 2022 · cited 111× · PMID 36551958 · DOI 10.3390/biomedicines10123202
Recent advances in the management of hepatocellular carcinoma.
Sankar K, Gong J, Osipov A, Miles SA, et al · · 2024 · cited 109× · PMID 37482076 · DOI 10.3350/cmh.2023.0125

Verify or expand the search:

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other The Clatterbridge Cancer Centre NHS Foundation Trust trials

Trials by the same sponsor.

NCT07342335 — Breaking Barriers to Research Access · recruiting
NCT07335120 — A Real-world Data and Sample Compendium of Frail and/or Multiply Treated Large B-cell Lymphoma · recruiting
NCT04603105 — CCP Cancer UK Companion Study · active not recruiting
NCT04622761 — Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Asses · Phase 2 · not yet recruiting
NCT03721757 — CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04268888 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Clatterbridge Cancer Centre NHS Foundation Trust
Last refreshed: 26 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04268888.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing